Ionis Pharmaceuticals IONS Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Ionis Pharmaceuticals (IONS) reported comprehensive income (loss), net of tax, attributable to parent of -$98.27M in Q1 2026.
- How has Ionis Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Ionis Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent increased by 32.3% year-over-year, from -$145.08M to -$98.27M.
- What is the long-term trend for Ionis Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a 4.9% compound annual growth rate (CAGR), from -$341.45M to -$375.86M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- The total change in company value including both profit and unrealized gains or losses.
- How do you interpret comprehensive income (loss), net of tax, attributable to parent?
- A comprehensive view of the company's total financial performance and equity changes.
- How does comprehensive income (loss), net of tax, attributable to parent compare across companies?
- Standardized accounting metric used to provide a complete picture of equity changes.